Mechanisms of Severe Acute Influenza Consortium (MOSAIC)

Influenza Clinical Trial

— MOSAIC  

Official title:

Mechanisms of Severe Acute Influenza Consortium (MOSAIC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00965354
• Other study ID #: CRO1367
• Secondary ID: 09/H0709/5209/MR
• Status: Completed
• Start date: December 2009
• Est. completion date: February 2011

Study information

• Verified date: July 2019
• Source: Imperial College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The ultimate goal of this collaborative, intensive study is to discover new and effective treatments and to develop better vaccines that can be used in future outbreaks of Influenza A. By integrating the information that we will gather, we will create a unique overview of how influenza causes illness and what might be done to improve patient management.

Description:

Influenza A is one of the best studied viruses, but continues to have a very large impact on human and animal health. In addition to causing outbreaks of winter flu, it sometimes mutates to create a new virus that spreads quickly around the world. It is puzzling that the same virus appears to cause minor or absent symptoms in some people while killing others. Much remains to be understood.

The investigators have assembled an unprecedented group of internationally renowned scientists from England and Scotland who will together focus on studying a few hundred people hospitalised during the current swine flu pandemic. Such a large scale project has never before been attempted, but we are now poised to work together and integrate the many recent advances in biomedical science that relate to understanding how influenza causes disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 131
• Est. completion date: February 2011
• Est. primary completion date: February 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Any patient admitted to hospital with suspected or confirmed influenza infection

Exclusion Criteria:

• Patients who do not give their consent

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Locations

Country	Name	City	State
United Kingdom	Aintree Hospitals NHS Trust	Liverpool
United Kingdom	Alder Hey Children's Foundation NHS Trust	Liverpool
United Kingdom	Liverpool Women's NHS Foundation Trust	Liverpool
United Kingdom	Royal Liverpool University Hospital	Liverpool
United Kingdom	Chelsea and Westminster Hospital NHS Foundation Trust	London
United Kingdom	Imperial College Healthcare NHS Trust	London
United Kingdom	Royal Brompton and Harefield NHS Foundation Trust	London
United Kingdom	Wirral University Teaching Hospital NHS Foundation Trust	Wirral

Sponsors (3)

Lead Sponsor	Collaborator
Imperial College London	Medical Research Council, Wellcome Trust

Country where clinical trial is conducted

United Kingdom, 

References & Publications (2)

Dunning J, Blankley S, Hoang LT, Cox M, Graham CM, James PL, Bloom CI, Chaussabel D, Banchereau J, Brett SJ, Moffatt MF, O'Garra A, Openshaw PJM; MOSAIC Investigators. Progression of whole-blood transcriptional signatures from interferon-induced to neutro — View Citation

Dunning J, Blankley S, Hoang LT, Cox M, Graham CM, James PL, Bloom CI, Chaussabel D, Banchereau J, Brett SJ; MOSAIC Investigators, Moffatt MF, O'Garra A, Openshaw PJM. Author Correction: Progression of whole-blood transcriptional signatures from interfero — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detailed clinical phenotype. Clinicopathological correlation will then be sought between the clinical phenotype and pathological parameters measured as per work packages.		3 years
Secondary	Response to drug treatment and the effect of drug resistance if that emerges.		3 years